Table 2.

Currently available inhibitors targeting the most frequently overexpressed genes reported in the present study.

Gene	Available inhibitors (examples)	Current stage
IGF2	IGFR/IR inhibitor (e.g., linsitinib)	Phase III trial in ACC patients (OSI-906)a
TOP2A	TOP2A inhibitors (e.g., aclarubicin)	Preclinical studies in ACC cellsb
CDK1	Pan-CDK inhibitors (e.g., flavopiridol)	Phase I/II trials ongoing in solid tumors Preclinical studies in ACC cellsc
CDK4	CDK4/6 inhibitors (e.g., palbociclib)	FDA and EMA approved for EGFR-negative breast cancer Phase II trials in liposarcoma Preclinical studies in ACC cellsd
PLK4	PLK4 inhibitor (fumarate)	Phase I trials ongoing in solid tumors
PLK1	PLK1 inhibitor (e.g., TKM-080301)	Phase I/II trials ongoing in solid tumors

^aFassnacht et al. (24);

^bJain et al., (26);

^cNilubol et al., (27);

^dFiorentini et al. (28).

FDA, Food and Drug Association; EMA, European Medical Association.

Sources: www.clinicaltrials.com, www.ema.europa.eu/en/medicines, www.fda.gov/drugs/informationondrugs/approveddrugs.